Valued editorial board member Jeffrey Cummings (University of Nevada, Las Vegas [UNLV], and Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) shares exciting insights from the session he co-chaired at AAIC20 entitled ‘Microbiome in Alzheimer’s Disease: Pathogenesis and Treatment Implications’.
Questions
1. Could you give us a brief overview of the role of the innate immune system in the progression of Alzheimer’s disease (AD)? (0:06)
2. What is known about the impact of alterations in the gut microbiota composition on neuroinflammation? (0:58)
3. What possible mechanisms may underlie the effect of the gut microbiome on the pathogenesis of AD? (1:40)
4. Could you tell us a little about GV-971, its mechanism of action and its clinical development to date? (2:11)
Disclosures: Prof. Cummings has provided consultation to Acadia, Actinogen, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven and United Neuroscience pharmaceutical and assessment companies. Prof. Cummings has stock options in Adamas, AnnovisBio, BiOasis and MedAvante. Prof. Cummings owns the copyright of the Neuropsychiatric Inventory. Prof. Cummings is supported by Keep Memory Alive (KMA); NIGMS grant P20GM109025; NINDS grant U01NS093334 and NIA grant R01AG053798.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Alzheimer’s Association International Conference (AAIC) 2020.
